REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients
Charles W Bishop, Akhtar Ashfaq, Joel Z Melnick, Enrique Vazquez-Escarpanter, Jonathan A Fialkow, PhD Stephen A Strugnell, John Choe, Kamyar Kalantar-Zadeh, Noah C Federman, David Ng, John S Adams
Nutrition, doi:10.1016/j.nut.2022.111899
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CONCLUSIONS In conclusion, ERC was effective in increasing serum total 25D to levels of at least 50 ng/mL in outpatients with mild to moderate COVID-19 and may have accelerated resolution of respiratory symptoms, suggesting mitigation of COVID-19 pneumonia risk. The positive findings from this RCT warrant confirmation in additional larger studies. Data Availability: Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.
References
Armas, Hollis, Heaney, Vitamin D 2 is much less effective than vitamin D 3 in humans, J Clin Endocrinol Metab
Bilezikian, Bikle, Hewison, Mechanisms in endocrinology:vitamin D and COVID-19, Eur J Endocrinol,
doi:10.1530/EJE-20-0665Bishop, Strugnell, Csomor, Extended-release calcifediol effectively raises serum total 25-hydroyxvitamin D even in overweight non-dialysis CKD patients with secondary hyperparathyroidism, Am J Nephrol
Borsche, Glauner, Mendel, COVID-19 mortality risk correlates inversely with vitamin D 3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D 3 : results of a systematic review and meta-analysis, Nutrients,
doi:10.3390/nu13103596Cannata-Andia, Diaz-Sottolano, Fernandez, A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D -a randomized multicenter international clinical trial, BMC Medicine
Didriksen, Build, Jakobsen, Vitamin D 3 increase in abdominal subcutaneous fat tissue after supplementation with vitamin D 3, Eur J Endocrinol
Didriksen, Grimnes, Hutchinson, The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels, Eu J Endocrinol
Ekwaru, Zwicker, Holick, The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers, Plos One
Gombart, Saito, Koeffler, Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates, BMC Genomics,
doi:10.1186/1471-2164-10-321Grant, Lahore, Mcdonnell, Evidence that vitamin D supplementation could reduce risk of Influenza and COVID-19 infections and deaths, Nutrients,
doi:10.3390/nu12040988Grant, Vitamin D's role in reducing risk of SARS-CoV-2 and COVID-19 incidence, severity, and death, Nutrients,
doi:10.3390/nu14010183Griffin, Hewison, Hopkin, Perspective: Vitamin D supplementation prevents rickets and acute respiratory infections when given as daily maintenance but not as intermittent bolus: implications for COVID-19, Clin Med
Hengist, Perkin, Gonzelez, Mobilizing vitamin D from adipose tissue: the potential impact of exercise, Nutr Bull
Holick, Binkley, Bischoff-Ferrari, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab
Jude, Ling, Allcock, Vitamin D deficiency is associated with higher hospitalization risk from COVID-19: a retrospective case-control study, J Clin Endocrinol Metab,
doi:10.1210/clinem/dgab439Maghbooli, Sahraian, Jamalimoghadamsiahkali, Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in hospitalized patients with COVID-19: a pilot multicenter, randomized, placebo-controlled, double-blinded clinical trial, Endocr Pract
Mazess, Bischoff-Ferrari, Hughes, Vitamin D: Bolus is bogus -a narrative review, JBMR Plus
Murai, Fernandes, Sales, Effect of a single high dose of vitamin D 3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial, JAMA,
doi:10.3390/nu13103596Nogues, Ovejero, Pineda-Moncusi, Calcifediol treatment and COVID-19-related outcomes, J Clin Endocrinol Metab
Powers, Guerrero, Leidy, Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza, BMC Infect Dis,
doi:10.1186/s12879-015-1330-0Qin, Zhou, Hu, Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin Infect Dis
Roizen, Long, Casella, Obesity decreases hepatic 25-hydroxylase activity causing low serum 25-hydroxyvitamin D, J Bone Miner Res
Sprague, Crawford, Melnick, Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease, Am J Nephrol
Wang, Joshi, Leopold, Association of vitamin D deficiency with COVID-19 infection severity: systematic review and meta-analysis, Clin Encrinol,
doi:10.1111/cen.14540White, Emerging roles of vitamin D-induced antimicrobial peptides in antiviral innate immunity, Nutrients,
doi:10.3390/nu14020284{ 'indexed': {'date-parts': [[2022, 11, 8]], 'date-time': '2022-11-08T05:45:46Z', 'timestamp': 1667886346908},
'reference-count': 0,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2022, 11, 1]],
'date-time': '2022-11-01T00:00:00Z',
'timestamp': 1667260800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2022, 11, 1]],
'date-time': '2022-11-01T00:00:00Z',
'timestamp': 1667260800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2022, 11]]},
'DOI': '10.1016/j.nut.2022.111899',
'type': 'journal-article',
'created': {'date-parts': [[2022, 11, 7]], 'date-time': '2022-11-07T17:15:49Z', 'timestamp': 1667841349000},
'page': '111899',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'REsCue Trial: Randomized Controlled Clinical Trial with Extended-Release Calcifediol in '
'Symptomatic COVID-19 Outpatients',
'prefix': '10.1016',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7877-6795',
'authenticated-orcid': False,
'given': 'Charles W.',
'family': 'Bishop',
'sequence': 'first',
'affiliation': []},
{'given': 'Akhtar', 'family': 'Ashfaq', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joel Z.', 'family': 'Melnick', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Enrique',
'family': 'Vazquez-Escarpanter',
'sequence': 'additional',
'affiliation': []},
{'given': 'Jonathan A.', 'family': 'Fialkow', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stephen A.', 'family': 'Strugnell', 'sequence': 'additional', 'affiliation': []},
{'given': 'John', 'family': 'Choe', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kamyar', 'family': 'Kalantar-Zadeh', 'sequence': 'additional', 'affiliation': []},
{'given': 'Noah C.', 'family': 'Federman', 'sequence': 'additional', 'affiliation': []},
{'given': 'David', 'family': 'Ng', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-9607-5020',
'authenticated-orcid': False,
'given': 'John S.',
'family': 'Adams',
'sequence': 'additional',
'affiliation': []}],
'member': '78',
'container-title': 'Nutrition',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0899900722003100?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S0899900722003100?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2022, 11, 7]],
'date-time': '2022-11-07T17:15:51Z',
'timestamp': 1667841351000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0899900722003100'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 11]]},
'references-count': 0,
'alternative-id': ['S0899900722003100'],
'URL': 'http://dx.doi.org/10.1016/j.nut.2022.111899',
'relation': {},
'ISSN': ['0899-9007'],
'subject': ['Nutrition and Dietetics', 'Endocrinology, Diabetes and Metabolism'],
'container-title-short': 'Nutrition',
'published': {'date-parts': [[2022, 11]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'REsCue Trial: Randomized Controlled Clinical Trial with Extended-Release '
'Calcifediol in Symptomatic COVID-19 Outpatients',
'name': 'articletitle',
'label': 'Article Title'},
{'value': 'Nutrition', 'name': 'journaltitle', 'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.nut.2022.111899',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2022 OPKO Health. Published by Elsevier Inc.',
'name': 'copyright',
'label': 'Copyright'}],
'article-number': '111899'}
